Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position […]

Open Orphan plc (ORPH) Demerger Update

Demerger Update Further to Open Orphan’s announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention to seek admission of its shares to trading on AIM, a market of the London Stock Exchange (“Admission”). Funds raised as part of Admission will be used primarily to fund the […]

Open Orphan (ORPH) Final Results to 31 December 2020

Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for […]

Open Orphan PLC (ORPH) Exercise of Warrants and Issue of Shares

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company has received notices of exercise of warrants over 539,654 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 191,051 ordinary shares and at a price of […]